| 异基因造血干细胞移植后巨细胞病毒感染的预先治疗 |
| |
| 引用本文： | 段连宁,丁丽,薛梅,刘静,闫红敏,朱玲,朱培瑜,韩红星,王恒湘,纪树荃.异基因造血干细胞移植后巨细胞病毒感染的预先治疗[J].临床血液学杂志,2009,22(2). |
| |
| 作者姓名： | 段连宁 丁丽 薛梅 刘静 闫红敏 朱玲 朱培瑜 韩红星 王恒湘 纪树荃 |
| |
| 作者单位： | 空军总医院血液科,北京,100036
|
| |
| 摘 要： | 目的:探讨预防治疗及预先治疗对异基因造血干细胞移植后CMV感染的干预作用.方法:225例异基因造血干细胞移植患者中160例接受预先治疗,65例接受预防治疗,用logistic回归模型分析影响CMV感染的危险因素.结果:预先治疗组与预防治疗组比较,CMVpp65抗原血症、CMV病和CMV病死亡率分别为28.1%(35.3%,P>0.05),1.9%(12.3%,P<0.05)和0.6%(10.7%,P<0.01).单倍体相合移植组出现CM-Vpp65血症33.0%(40.0%,P>0.05)、CMV病发生率1.9%(12.0%,P<0.05)、死亡率0.0%(10.0%,P<0.05),均低于相合移植.单倍体相合移植组中CMVpp65阳性发生的主要危险因素为重症GVHD、移植前给予抗CMV治疗以及是否混合其他严重感染.结论:异基因移植后预先治疗优于预防治疗,可以明显减低CMV病的发生和死亡.
|
| 关 键 词： | 移植 巨细胞病毒 感染 治疗 更昔洛韦 |
Study of pre-emptive therapy against CMV infection in allogeneic HSCT |
| |
| DUAN Lianning DING Li XUE Mei LIU Jing YAN Hongmin ZHU LingZHU Peiyu HAN Hongxing WANG Hengxiang JI Shuquan.Study of pre-emptive therapy against CMV infection in allogeneic HSCT[J].Journal of Clinical Hematology,2009,22(2). |
| |
| Authors: | DUAN Lianning DING Li XUE Mei LIU Jing YAN Hongmin ZHU LingZHU Peiyu HAN Hongxing WANG Hengxiang JI Shuquan |
| |
| Institution: | Department of Hematology;Air Force General Hospital of PLA;Beijing;100036;China |
| |
| Abstract: | Objective:To explore the impact of pre-emptive therapy and prosphylactic therapy on CMV infection in allogeneic HSCT. Method:160 of 225 patients receiving allogeneic HSCT were given pre-emptive therapy while 65 patients were given prosphylactic therapy. Risk factors of CMV infection were investigated by logistic regression analysis. Result:CMV pp65 antigenemia rate, CMV disease rate and death rate were 28.1%, 1.9% and 0.6% in pre-emptive therapy group, but much lower in prosphylactic therapy group (35.3%,P>... |
| |
| Keywords: | transplantation CMV infection therapy ganciclovir |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
